National Institute of Pharmaceutical Education and Research, S.A.S. Nagar

What is the placement record at National Institute of Pharmaceutical Education and Research, S.A.S. Nagar?

In the 2025 placement cycle, National Institute of Pharmaceutical Education and Research, S.A.S. Nagar (NIPER Mohali) placed 79.00% of its eligible postgraduates, with the highest package reaching Rs. 15 LPA (Rs. 15,00,000) offered by Pfizer and a NIRF-reported median of about Rs. 6.05 LPA. That is up from 76.90% placed and a Rs. 12 LPA (Rs. 12,00,000) high in 2024. As a government institute of national importance under the Department of Pharmaceuticals, NIPER Mohali draws core pharma and biotech recruiters such as Dr. Reddy's, Novartis, Zydus, Syngene, Biocon and Sun Pharma, with most offers landing in the Rs. 5.5-7 LPA band. The 2025 season generated 250+ offers from 40+ companies, a roughly 12% rise over 2024.

NIPER Mohali is a pure postgraduate and doctoral research institution (M.Pharm, M.S. Pharm, MBA Pharm, M.Tech and Ph.D), so its placement record reflects specialised pharma hiring rather than mass campus recruitment. The sections below break the numbers down year by year, name the recruiters, and explain which programs and sectors drive the strongest outcomes for 2026 aspirants.

Year-Wise Placement Statistics

The table below answers the single most-searched question about NIPER Mohali: how have packages and placement percentages moved across years? It compiles the highest, average and median package alongside the percentage placed for 2026, 2025 and 2024. Read it top to bottom to see the trajectory; the 2026 cycle was still in progress at the time of writing (NIPER JEE 2026 was held in June 2026), so its final figures are not yet published. The 2025 and 2024 highest packages and placement percentages are the institute's confirmed figures.

The clearest takeaway is upward momentum: the placement rate climbed from 76.90% in 2024 to 79.00% in 2025, while the ceiling package rose 25%, from Rs. 12 LPA to Rs. 15 LPA. NIPER Mohali does not publish a single official mean salary (hence the reported ranges above), but the NIRF median moving to roughly Rs. 6.05 LPA in 2025 shows the typical graduate, not just the top earner, gained ground. For a 2026 applicant, the pattern signals a stable-to-improving market for NIPER Mohali pharma postgraduates.

Top Recruiters at National Institute of Pharmaceutical Education and Research, S.A.S. Nagar

More than 40 companies recruited from NIPER Mohali in the 2025 cycle, concentrated in pharmaceuticals, biotechnology, clinical research and pharma analytics. The verifiable recruiters reported across the 2024-2025 seasons, grouped by sector, are listed below. Dr. Reddy's was among the largest single recruiters (35+ hires reported in 2025), while Pfizer anchored the top of the salary range.

The recruiter list underscores that NIPER Mohali placements are driven by the core Indian and multinational pharma industry rather than IT or generic campus hirers. Repeat visitors such as Dr. Reddy's, Novartis, GSK and Zydus return year after year, which matters for 2026 candidates because consistent recruiters tend to maintain or grow their intake. Roles span formulation R&D, regulatory affairs, analytical development and medical/clinical functions.

Sector & Role-Wise Breakdown

The next table answers what kinds of jobs NIPER Mohali graduates actually take and what they pay. It maps the dominant sectors and roles in the 2025 cycle to their approximate share of offers and typical package band. Research and development was overwhelmingly the largest destination, with regulatory affairs and formulation/analytical roles making up most of the rest. Use it to gauge where a NIPER Mohali degree most reliably leads.

The standout point is how R&D-heavy NIPER Mohali outcomes are: roughly three in four 2025 offers were research roles, reflecting the institute's research-first identity. Program-wise, M.Pharm was the strongest performer in 2025 with around 120 placements (more than half of all PG offers) at an average near Rs. 7 LPA from recruiters like Dr. Reddy's, while Ph.D candidates averaged around Rs. 5 LPA. For 2026 aspirants, this means formulation and R&D-oriented specialisations have historically seen the deepest hiring at NIPER Mohali.

Placement Trend Analysis

NIPER Mohali's placement trajectory is moving steadily upward across 2024 and 2025. The headline placement rate rose from 76.90% in 2024 to 79.00% in 2025, the highest package grew from Rs. 12 LPA to Rs. 15 LPA, and the median package improved to roughly Rs. 6.05 LPA per NIRF 2025. Total offers crossed 250 in 2025 from 40+ companies, reported as about 12% growth over the prior year.

Three forces explain the rise. First, sustained demand from large generics and biotech firms (Dr. Reddy's, Zydus, Syngene, Biocon) keeps the R&D pipeline full, and these recruiters expanded intake in 2025. Second, NIPER Mohali's placement cell scaled up support with 30+ employability workshops, technical masterclasses and mock interviews, plus 150+ internship opportunities, several of which convert into pre-placement offers. Third, the institute's reputation as a top-ranked pharmacy school keeps premium recruiters like Pfizer and Novartis anchoring the upper salary band. The caveat for 2026 candidates is that outcomes remain concentrated in pharma R&D and regulatory roles, and the typical package (Rs. 6-7 LPA) sits well below the Rs. 15 LPA headline, so the median is the realistic benchmark.